CANDEL THERAPEUTICS INC (CADL)
US1374041093 - Common Stock
Taking everything into account, CADL scores 1 out of 10 in our fundamental rating. CADL was compared to 582 industry peers in the Biotechnology industry. Both the profitability and financial health of CADL have multiple concerns. CADL is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CADL had negative earnings in the past year.
CADL had a negative operating cash flow in the past year.
In the past 5 years CADL always reported negative net income.
CADL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CADL's Return On Assets of -92.10% is on the low side compared to the rest of the industry. CADL is outperformed by 74.70% of its industry peers.
CADL has a worse Return On Equity (-297.72%) than 75.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -92.1% | ||
| ROE | -297.72% | ||
| ROIC | N/A |
ROA(3y)-52.25%
ROA(5y)-44.18%
ROE(3y)-131.12%
ROE(5y)-96.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CADL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CADL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CADL has been increased compared to 1 year ago.
Compared to 1 year ago, CADL has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.28, we must say that CADL is in the distress zone and has some risk of bankruptcy.
CADL has a Altman-Z score (-2.28) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.97 indicates that CADL is somewhat dependend on debt financing.
CADL has a worse Debt to Equity ratio (0.97) than 78.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.28 |
ROIC/WACCN/A
WACC9.01%
2.3 Liquidity
CADL has a Current Ratio of 2.59. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CADL (2.59) is worse than 72.10% of its industry peers.
CADL has a Quick Ratio of 2.59. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.59, CADL is doing worse than 70.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.59 | ||
| Quick Ratio | 2.59 |
3. Growth
3.1 Past
The earnings per share for CADL have decreased strongly by -21.43% in the last year.
Looking at the last year, CADL shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
CADL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.14% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.44%
EPS Next 2Y29.14%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CADL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CADL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CADL's earnings are expected to grow with 29.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.14%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CADL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CANDEL THERAPEUTICS INC
NASDAQ:CADL (6/12/2024, 7:23:54 PM)
After market: 7.5337 -0.05 (-0.61%)7.58
+0.03 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap225.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -92.1% | ||
| ROE | -297.72% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.59 | ||
| Quick Ratio | 2.59 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y40.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y